GB0511267D0 - Indol derivatives and their use as kinase inhibitors - Google Patents

Indol derivatives and their use as kinase inhibitors

Info

Publication number
GB0511267D0
GB0511267D0 GBGB0511267.7A GB0511267A GB0511267D0 GB 0511267 D0 GB0511267 D0 GB 0511267D0 GB 0511267 A GB0511267 A GB 0511267A GB 0511267 D0 GB0511267 D0 GB 0511267D0
Authority
GB
United Kingdom
Prior art keywords
kinase inhibitors
indol derivatives
indol
derivatives
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GBGB0511267.7A
Other versions
GB2410744A (en
GB2410744B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/307,097 external-priority patent/US6699863B1/en
Priority claimed from US10/389,416 external-priority patent/US6747025B1/en
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of GB0511267D0 publication Critical patent/GB0511267D0/en
Publication of GB2410744A publication Critical patent/GB2410744A/en
Application granted granted Critical
Publication of GB2410744B publication Critical patent/GB2410744B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
GB0511267A 2002-11-27 2003-11-19 Kinase inhibitors for the treatment of disease Expired - Fee Related GB2410744B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30697502A 2002-11-27 2002-11-27
US10/307,097 US6699863B1 (en) 2002-11-27 2002-11-27 Kinase inhibitors for the treatment of disease
US10/389,416 US6747025B1 (en) 2002-11-27 2003-03-13 Kinase inhibitors for the treatment of disease
PCT/US2003/036988 WO2004050621A2 (en) 2002-11-27 2003-11-19 Indol derivatives and their use as kinase inhibitors

Publications (3)

Publication Number Publication Date
GB0511267D0 true GB0511267D0 (en) 2005-07-13
GB2410744A GB2410744A (en) 2005-08-10
GB2410744B GB2410744B (en) 2006-04-12

Family

ID=32475339

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0511267A Expired - Fee Related GB2410744B (en) 2002-11-27 2003-11-19 Kinase inhibitors for the treatment of disease

Country Status (7)

Country Link
AU (1) AU2003295658A1 (en)
BR (1) BR0316744A (en)
CA (1) CA2507780A1 (en)
DE (1) DE10393799T5 (en)
ES (1) ES2292329B2 (en)
GB (1) GB2410744B (en)
WO (1) WO2004050621A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013239B1 (en) * 2005-04-28 2010-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Novel compounds for treating inflammatory diseases
US8338415B2 (en) 2006-01-24 2012-12-25 Allergan, Inc. Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
US7977351B2 (en) * 2006-03-22 2011-07-12 Allergan, Inc. Heteroaryl dihydroindolones as kinase inhibitors
CN104211632B (en) * 2013-05-31 2016-12-28 中国人民解放军军事医学科学院放射与辐射医学研究所 2 indolone derivatives with tyrosine-kinase enzyme inhibition activity and preparation method and application
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY128450A (en) * 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
AR038957A1 (en) * 2001-08-15 2005-02-02 Pharmacia Corp COMBINATION THERAPY FOR CANCER TREATMENT

Also Published As

Publication number Publication date
ES2292329A1 (en) 2008-03-01
AU2003295658A1 (en) 2004-06-23
CA2507780A1 (en) 2004-06-17
GB2410744A (en) 2005-08-10
ES2292329B2 (en) 2009-09-16
GB2410744B (en) 2006-04-12
WO2004050621A3 (en) 2004-07-15
WO2004050621A2 (en) 2004-06-17
BR0316744A (en) 2005-10-18
DE10393799T5 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
PL376789A1 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
ZA200500680B (en) Quinoline derivatives and their use as mycrobacterial inhibitors
PL1648426T3 (en) Benzimidazole derivatives and their use as protein kinases inhibitors
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
EP1496910A4 (en) Kinase inhibitors
PL403456A1 (en) 5-phenylthiazole derivatives and their use as Pi3 kinase inhibitors
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
IL176233A0 (en) Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors
AU2003271566A8 (en) Pyrrolopyrazines as kinase inhibitors
EP1539763A4 (en) Azaindole kinase inhibitors
AU2003259749A1 (en) 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
SI1569907T1 (en) Nicotinamide-based kinase inhibitors
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
HK1061854A1 (en) Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
AU2003299651A8 (en) Tyrosine kinase inhibitors
HK1079518A1 (en) Quinazolinone derivatives and their use as cb agonists
EP1558609A4 (en) Kinase inhibitors
IL172257A0 (en) Substituted pyrrole derivatives and their use as hmg-co inhibitors
AU2003298942A8 (en) Tyrosine kinase inhibitors
AU2003254051A8 (en) Pyrazolopyrimidines as kinase inhibitors
PL378116A1 (en) Heterocyclic kinase inhibitors
AU2003220437A1 (en) Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
PL374581A1 (en) Diaminothiazoles and use thereof as cdk4 inhibitors

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20081119